|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ACOT9 |
Gene summary for ACOT9 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ACOT9 | Gene ID | 23597 |
| Gene name | acyl-CoA thioesterase 9 | |
| Gene Alias | ACATE2 | |
| Cytomap | Xp22.11 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9Y305 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23597 | ACOT9 | LZE4T | Human | Esophagus | ESCC | 7.14e-14 | 3.87e-01 | 0.0811 |
| 23597 | ACOT9 | LZE7T | Human | Esophagus | ESCC | 2.65e-08 | 4.58e-01 | 0.0667 |
| 23597 | ACOT9 | LZE8T | Human | Esophagus | ESCC | 5.54e-06 | 2.95e-01 | 0.067 |
| 23597 | ACOT9 | LZE22T | Human | Esophagus | ESCC | 3.24e-06 | 2.69e-01 | 0.068 |
| 23597 | ACOT9 | LZE24T | Human | Esophagus | ESCC | 1.37e-04 | 8.57e-02 | 0.0596 |
| 23597 | ACOT9 | LZE6T | Human | Esophagus | ESCC | 2.19e-06 | 2.20e-01 | 0.0845 |
| 23597 | ACOT9 | P1T-E | Human | Esophagus | ESCC | 1.78e-04 | 1.76e-01 | 0.0875 |
| 23597 | ACOT9 | P2T-E | Human | Esophagus | ESCC | 1.04e-10 | 3.21e-01 | 0.1177 |
| 23597 | ACOT9 | P4T-E | Human | Esophagus | ESCC | 5.82e-19 | 3.51e-01 | 0.1323 |
| 23597 | ACOT9 | P5T-E | Human | Esophagus | ESCC | 5.91e-24 | 5.43e-01 | 0.1327 |
| 23597 | ACOT9 | P8T-E | Human | Esophagus | ESCC | 6.63e-32 | 5.90e-01 | 0.0889 |
| 23597 | ACOT9 | P9T-E | Human | Esophagus | ESCC | 8.51e-10 | 2.19e-01 | 0.1131 |
| 23597 | ACOT9 | P10T-E | Human | Esophagus | ESCC | 3.49e-14 | 2.53e-01 | 0.116 |
| 23597 | ACOT9 | P11T-E | Human | Esophagus | ESCC | 1.07e-16 | 6.88e-01 | 0.1426 |
| 23597 | ACOT9 | P12T-E | Human | Esophagus | ESCC | 9.43e-19 | 4.38e-01 | 0.1122 |
| 23597 | ACOT9 | P15T-E | Human | Esophagus | ESCC | 1.06e-08 | 1.96e-01 | 0.1149 |
| 23597 | ACOT9 | P16T-E | Human | Esophagus | ESCC | 1.48e-18 | 3.33e-01 | 0.1153 |
| 23597 | ACOT9 | P17T-E | Human | Esophagus | ESCC | 2.40e-09 | 3.50e-01 | 0.1278 |
| 23597 | ACOT9 | P19T-E | Human | Esophagus | ESCC | 2.98e-11 | 1.74e+00 | 0.1662 |
| 23597 | ACOT9 | P20T-E | Human | Esophagus | ESCC | 7.13e-04 | 8.86e-02 | 0.1124 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006753110 | Esophagus | ESCC | nucleoside phosphate metabolic process | 288/8552 | 497/18723 | 1.80e-08 | 3.50e-07 | 288 |
| GO:0019693111 | Esophagus | ESCC | ribose phosphate metabolic process | 234/8552 | 396/18723 | 4.24e-08 | 7.76e-07 | 234 |
| GO:0009117111 | Esophagus | ESCC | nucleotide metabolic process | 282/8552 | 489/18723 | 4.70e-08 | 8.50e-07 | 282 |
| GO:00067906 | Esophagus | ESCC | sulfur compound metabolic process | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
| GO:0009259111 | Esophagus | ESCC | ribonucleotide metabolic process | 224/8552 | 385/18723 | 4.41e-07 | 6.00e-06 | 224 |
| GO:0072521111 | Esophagus | ESCC | purine-containing compound metabolic process | 238/8552 | 416/18723 | 1.20e-06 | 1.49e-05 | 238 |
| GO:0009150111 | Esophagus | ESCC | purine ribonucleotide metabolic process | 213/8552 | 368/18723 | 1.40e-06 | 1.69e-05 | 213 |
| GO:0006163111 | Esophagus | ESCC | purine nucleotide metabolic process | 226/8552 | 396/18723 | 2.81e-06 | 3.21e-05 | 226 |
| GO:00338655 | Esophagus | ESCC | nucleoside bisphosphate metabolic process | 77/8552 | 128/18723 | 6.71e-04 | 3.55e-03 | 77 |
| GO:00338755 | Esophagus | ESCC | ribonucleoside bisphosphate metabolic process | 77/8552 | 128/18723 | 6.71e-04 | 3.55e-03 | 77 |
| GO:00340325 | Esophagus | ESCC | purine nucleoside bisphosphate metabolic process | 77/8552 | 128/18723 | 6.71e-04 | 3.55e-03 | 77 |
| GO:00066374 | Esophagus | ESCC | acyl-CoA metabolic process | 55/8552 | 96/18723 | 1.45e-02 | 4.71e-02 | 55 |
| GO:00353834 | Esophagus | ESCC | thioester metabolic process | 55/8552 | 96/18723 | 1.45e-02 | 4.71e-02 | 55 |
| GO:000911722 | Liver | HCC | nucleotide metabolic process | 300/7958 | 489/18723 | 1.61e-17 | 1.71e-15 | 300 |
| GO:000675322 | Liver | HCC | nucleoside phosphate metabolic process | 304/7958 | 497/18723 | 1.78e-17 | 1.85e-15 | 304 |
| GO:001969322 | Liver | HCC | ribose phosphate metabolic process | 248/7958 | 396/18723 | 3.15e-16 | 2.70e-14 | 248 |
| GO:000925922 | Liver | HCC | ribonucleotide metabolic process | 240/7958 | 385/18723 | 2.07e-15 | 1.51e-13 | 240 |
| GO:000679021 | Liver | HCC | sulfur compound metabolic process | 212/7958 | 339/18723 | 5.60e-14 | 3.39e-12 | 212 |
| GO:000915022 | Liver | HCC | purine ribonucleotide metabolic process | 226/7958 | 368/18723 | 1.36e-13 | 7.69e-12 | 226 |
| GO:007252122 | Liver | HCC | purine-containing compound metabolic process | 250/7958 | 416/18723 | 2.26e-13 | 1.24e-11 | 250 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ACOT9 | SNV | Missense_Mutation | novel | c.86N>G | p.Pro29Arg | p.P29R | Q9Y305 | protein_coding | tolerated_low_confidence(0.21) | benign(0.075) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ACOT9 | SNV | Missense_Mutation | novel | c.947N>G | p.Phe316Cys | p.F316C | Q9Y305 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ACOT9 | SNV | Missense_Mutation | c.304C>T | p.Pro102Ser | p.P102S | Q9Y305 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| ACOT9 | SNV | Missense_Mutation | novel | c.845N>G | p.Thr282Ser | p.T282S | Q9Y305 | protein_coding | tolerated(0.54) | benign(0.044) | TCGA-PE-A5DC-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| ACOT9 | SNV | Missense_Mutation | novel | c.182N>T | p.Thr61Ile | p.T61I | Q9Y305 | protein_coding | deleterious(0.03) | possibly_damaging(0.735) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ACOT9 | SNV | Missense_Mutation | novel | c.112N>T | p.His38Tyr | p.H38Y | Q9Y305 | protein_coding | tolerated_low_confidence(0.49) | benign(0.058) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| ACOT9 | SNV | Missense_Mutation | c.1225N>C | p.Glu409Gln | p.E409Q | Q9Y305 | protein_coding | tolerated(0.18) | benign(0.361) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ACOT9 | SNV | Missense_Mutation | novel | c.806C>A | p.Thr269Asn | p.T269N | Q9Y305 | protein_coding | deleterious(0.04) | benign(0.306) | TCGA-VS-A959-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| ACOT9 | SNV | Missense_Mutation | c.155A>C | p.Lys52Thr | p.K52T | Q9Y305 | protein_coding | tolerated(0.11) | benign(0.009) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
| ACOT9 | SNV | Missense_Mutation | novel | c.100A>C | p.Ile34Leu | p.I34L | Q9Y305 | protein_coding | tolerated_low_confidence(0.71) | benign(0) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |